Richard Pestell - Publications#

10 Most Significant Publications

1. Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and Pestell, R.G., Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995 Oct 6; 270(40): p. 23589-97.
Citations 1,071, Impact factor 4.8,

2. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R.G., and Ben-Ze'ev, A., The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999 May 11; 96(10): p. 5522-7.
Citations 2,803, Impact factor 12.8,

3. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M.R., Pestell, R.G., Yuan, F., Auborn, K.J., Goldberg, I.D., and Rosen, E.M., BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999 May 21; 284(5418): p. 1354-6.
Citations 659, Impact factor 63.8,

4. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., and Darnell, J.E., Jr., Stat3 as an oncogene. Cell. 1999 Aug 6; 98(3): p. 295-303.
Citations, 3,626, Impact factor 66.85,

5. Fu, M., Wang, C., Reutens, A.T., Wang, J., Angeletti, R.H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.L., and Pestell, R.G., p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000 Jul 7;. 275 (27), 20853-20860.
Citations 450, Impact factor 4.8,

6. Lee, R.J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G.K., 3rd, Siegel, P.M., Hung, M.C., Yarden, Y., Horowitz, J.M., Muller, W.J., and Pestell, R.G., Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000 Jan; 20(2): p. 672-83.
Citations 421, Impact factor 5.1, Significance.

This publication served as the reference citations in the IND (investigational new drug) application to the FDA for the initial clinical research programs with the CDK inhibitors (palbociclib, NCT02947685). Palbociclib is now the standard of care for the treatment of advanced breast cancers (ABC)).

7. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, M.P., Russell, R.G., Mueller, S.C., Ojeifo, J., Chen, W.S., Hay, N., and Pestell, R.G., Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA. 2007 May 1; 104(18): p. 7438-43.
Citations: 233, Impact factor: 12.8,

8. Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M.C., Liu, M., Wu, K., Whittle, J., Ju, X., Hyslop, T., McCue, P., and Pestell, R.G., A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol. 2008 Aug 11; 182(3): p. 509-17,
Citations: 438, Impact factor: 8.1,

9. Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A.K., Frank, P.G., Casimiro, M.C., Wang, C., Fortina, P., Addya, S., Pestell, R.G., Martinez-Outschoorn, U.E., Sotgia, F., and Lisanti, M.P., The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009 Dec; 8(23): p. 3984-4001
Citations: 1,430, Impact factor: 5.17,

10. Velasco-Velázquez M, Jiao X, de la Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012 Aug 1;72(15):3839-50. Epub 2012 May 25

Citations 310, Impact factor 13.3, Significance. This 2012 publication provided conceptual support for clinical trials using CCR5 inhibitors (NCT03274804, NCT04504942, NCT04721301 and NCT03631407 (2018)). These studies were the basis for my issued patents (US Patent No. 9,453,836. “Use of modulators of CCR5 in the treatment of cancer and cancer metastasis”), the receipt of the Advance Global Australian Award in Biotechnology (2014), and the formation of ProstaGene LLC. ProstaGene LLC was sold to CytoDyn (2018), and the clinical trial that I submitted to the FDA (11/2018, NCT03838367), received fast track designation 5/2019, and showed ~80% patient response rate (Cristofanilli, Cancer Research 82, P5-17-08-P5-17-08, 2021). The subsequent trial NCT04504942 showed “improved median progression free survival (mPFS)” and “median overall survival”. (our recent review PMID: 37759462).